Clinical trial

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

NCT01497262

Study summary

ClinicalTrials.gov

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Fingolimod Normalized identity: fingolimod View linked drug · Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-02-01

PhasePHASE3

Conditions

Multiple Sclerosisverified · MONDO: multiple sclerosis

Interventions

FingolimodDRUG · verified · RxNorm: fingolimod

Sponsors & collaborators

Novartis Pharmaceuticalslead sponsor

Mapped research locations

Mexico CityMexico City, Mexico2 BogotáColombia2 Rio de JaneiroRio de Janeiro, Brazil2 San Miguel de TucumánTucumán Province, Argentina2 Porto AlegreRio Grande do Sul, Brazil1 CórdobaArgentina1 Kuala LumpurMalaysia1 MonterreyNuevo León, Mexico1 CaliColombia1 BarranquillaAtlántico, Colombia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01497262 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.